Vigna Elisa, Cavalieri Simona, Ailles Laurie, Geuna Massimo, Loew Rainer, Bujard Hermann, Naldini Luigi
Institute for Cancer Research and Treatment, University of Torino Medical School, Strada Provinciale 142, 10060 Candiolo, Italy.
Mol Ther. 2002 Mar;5(3):252-61. doi: 10.1006/mthe.2002.0542.
We developed a panel of lentiviral vectors that displayed tetracycline-regulated transgene expression over two orders of magnitude in bulk, non-selected populations of transduced cells in vitro and in vivo. The robust expression and homogeneous response indicated that most transduced vector genomes were transcription competent and responsive to regulation, providing the lentiviral vector with a novel competitive advantage for gene transfer. After ex vivo transduction and transplantation of cord blood CD34+ cells into NOD/SCID mice, reporter gene expression could be switched "on" and "off" in human hematopoietic cells in vivo for prolonged times, proving integration of the regulated expression system into long-term repopulating cells. By vector injection into established tumor grafts, we achieved efficient delivery and quantitative regulation of transgene expression in vivo. By these approaches, gene function studies can now be performed in in vivo models of human hematopoiesis and cancer. In the future, regulated lentiviral vectors will improve the safety and efficacy of gene therapy.
我们开发了一组慢病毒载体,其在体外和体内转导细胞的大量未选择群体中,四环素调控的转基因表达范围跨越两个数量级。强劲的表达和均匀的反应表明,大多数转导的载体基因组具有转录活性且对调控有反应,这为慢病毒载体在基因传递方面提供了一种新的竞争优势。在将脐血CD34+细胞进行体外转导并移植到NOD/SCID小鼠体内后,报告基因表达能够在体内的人类造血细胞中长时间“开启”和“关闭”,证明了调控表达系统整合到长期重建细胞中。通过将载体注射到已建立的肿瘤移植物中,我们在体内实现了转基因表达的高效递送和定量调控。通过这些方法,现在可以在人类造血和癌症的体内模型中进行基因功能研究。未来,调控慢病毒载体将提高基因治疗的安全性和有效性。